Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2017, Article ID 4810672, 9 pages
https://doi.org/10.1155/2017/4810672
Review Article

Deciphering the Roles of Thiazolidinediones and PPAR in Bladder Cancer

1Center for Hypertension and Personalized Medicine, Department of Physiology & Pharmacology, University of Toledo College of Medicine, Toledo, OH 43614, USA
2Department of Urology, University of Toledo College of Medicine, Toledo, OH 43614, USA

Correspondence should be addressed to Terry D. Hinds; ude.odelotu@sdnih.yrret

Received 13 October 2016; Accepted 12 February 2017; Published 28 February 2017

Academic Editor: Stefano Caruso

Copyright © 2017 Melody Chiu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Park, D. E. Citrin, P. K. Agarwal, and A. B. Apolo, “Multimodal management of muscle-invasive bladder cancer,” Current Problems in Cancer, vol. 38, no. 3, pp. 80–108, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. G. M. Dancik, “An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancer,” BMC Urology, vol. 15, no. 1, article 59, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Langle, C. Lodillinsky, D. Belgorosky, E. O. Sandes, and A. M. Eiján, “Role of peroxisome proliferator activated receptor-gamma in bacillus calmette-Guérin bladder cancer therapy,” Journal of Urology, vol. 188, no. 6, pp. 2384–2390, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. American Cancer Society, Bladder Cancer, ACS, 2014.
  5. M. C. Hall, S. S. Chang, G. Dalbagni et al., “Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update,” Journal of Urology, vol. 178, no. 6, pp. 2314–2330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. L. McBeth, M. Grabnar, S. Selman, and T. D. Hinds, “Involvement of the androgen and glucocorticoid receptors in bladder cancer,” International Journal of Endocrinology, vol. 2015, Article ID 384860, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Chu, M. Wang, and Z. Zhang, “Bladder cancer epidemiology and genetic susceptibility,” Journal of Biomedical Research, vol. 27, no. 3, pp. 170–178, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Fang, B. Yao, Y. Yan et al., “Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies,” Diabetes Technology and Therapeutics, vol. 15, no. 11, pp. 914–922, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. Centers for Disease Control and Prevention, National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014, CDC, Atlanta, Ga, USA, 2014.
  10. M. E. Goossens, M. P. Zeegers, M. T. Bazelier, M. L. De Bruin, F. Buntinx, and F. De Vries, “Risk of bladder cancer in patients with diabetes: a retrospective cohort study,” BMJ Open, vol. 5, no. 6, Article ID e007470, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. A. T. Kharroubi and H. M. Darwish, “Diabetes mellitus: the epidemic of the century,” World Journal of Diabetes, vol. 6, no. 6, pp. 850–867, 2015. View at Publisher · View at Google Scholar
  12. J. D. Lewis, A. Ferrara, T. Peng et al., “Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study,” Diabetes Care, vol. 34, no. 4, pp. 916–922, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. R. A. Lubet, S. M. Fischer, V. E. Steele, M. M. Juliana, R. Desmond, and C. J. Grubbs, “Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers,” International Journal of Cancer, vol. 123, no. 10, pp. 2254–2259, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Liu, T. Feng, N. Zhu et al., “Identification of a novel selective agonist of PPARgamma with no promotion of adipogenesis and less inhibition of osteoblastogenesis,” Scientific Reports, vol. 5, article 9530, 2015. View at Google Scholar
  15. Y. B. Esterson, K. Zhang, S. Koppaka et al., “Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients,” Journal of Investigative Medicine, vol. 61, no. 8, pp. 1152–1160, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Horita, M. Nakamura, N. Satoh, M. Suzuki, and G. Seki, “Thiazolidinediones and edema: recent advances in the pathogenesis of Thiazolidinediones-induced renal sodium retention,” PPAR Research, vol. 2015, Article ID 646423, 7 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Guan, Y. Zhang, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans,” American Journal of Physiology—Renal Physiology, vol. 273, no. 6, pp. F1013–F1022, 1997. View at Google Scholar · View at Scopus
  18. F. L. Egerod, N. Brünner, J. E. Svendsen, and M. B. Oleksiewicz, “PPARα and PPARγ are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium,” Journal of Applied Toxicology, vol. 30, no. 2, pp. 151–162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. B. A. Beamer, C. Negri, C.-J. Yen et al., “Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPARγ) gene,” Biochemical and Biophysical Research Communications, vol. 233, no. 3, pp. 756–759, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Sabatino, A. Fucci, M. Pancione, and V. Colantuoni, “PPARG epigenetic deregulation and its role in colorectal tumorigenesis,” PPAR Research, vol. 2012, Article ID 687492, 12 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Grygiel-Górniak, “Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications—a review,” Nutrition Journal, vol. 13, no. 1, article 17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Janani and B. D. Ranjitha Kumari, “PPAR gamma gene—a review,” Diabetes and Metabolic Syndrome: Clinical Research and Reviews, vol. 9, no. 1, pp. 46–50, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Fuentes, L. Guzmán-Jofre, R. Moore-Carrasco, and I. Palomo, “Role of PPARs in inflammatory processes associated with metabolic syndrome (Review),” Molecular medicine reports, vol. 8, no. 6, pp. 1611–1616, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. J. U. Scher and M. H. Pillinger, “15d-PGJ2: the anti-inflammatory prostaglandin?” Clinical Immunology, vol. 114, no. 2, pp. 100–109, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. D. E. Stec, K. John, C. J. Trabbic et al., “Bilirubin binding to PPARα inhibits lipid accumulation,” PLoS ONE, vol. 11, no. 4, Article ID e0153427, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. T. D. Hinds Jr., L. A. Stechschulte, H. A. Cash et al., “Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid receptor and peroxisome proliferator-activated receptor-γ (PPARγ),” Journal of Biological Chemistry, vol. 286, no. 50, pp. 42911–42922, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Noble, M. O. Baerlocher, and J. Silverberg, “Management of type 2 diabetes mellitus. Role of thiazolidinediones,” Canadian Family Physician, vol. 51, pp. 683–687, 2005. View at Google Scholar · View at Scopus
  28. N. D. Shah, V. M. Montori, H. M. Krumholz, K. Tu, G. C. Alexander, and C. A. Jackevicius, “Responding to an FDA warning—geographic variation in the use of rosiglitazone,” New England Journal of Medicine, vol. 363, no. 22, pp. 2081–2084, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Mamtani, K. Haynes, W. B. Bilker et al., “Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study,” Journal of the National Cancer Institute, vol. 104, no. 18, pp. 1411–1421, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. S.-S. Choi, J. Park, and J. H. Choi, “Revisiting PPARγ as a target for the treatment of metabolic disorders,” BMB Reports, vol. 47, no. 11, pp. 599–608, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. F.-Y. Hsiao, P.-H. Hsieh, W.-F. Huang, Y.-W. Tsai, and C.-S. Gau, “Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: A Nested Case-control Study,” Drug Safety, vol. 36, no. 8, pp. 643–649, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. A. M. Gallagher, L. Smeeth, S. Seabroke, H. G. M. Leufkens, and T. P. van Staa, “Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data,” PLOS ONE, vol. 6, no. 12, Article ID e28157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. H. J. Burstein, G. D. Demetri, E. Mueller, P. Sarraf, B. M. Spiegelman, and E. P. Winer, “Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study,” Breast Cancer Research and Treatment, vol. 79, no. 3, pp. 391–397, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Butler, S. H. Mitchell, D. J. Tindall, and C. Y. F. Young, “Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-Deoxy-Δ12,14-prostaglandin J2,” Cell Growth and Differentiation, vol. 11, no. 1, pp. 49–61, 2000. View at Google Scholar · View at Scopus
  36. K.-I. Inoue, Y. Kawahito, Y. Tsubouchi et al., “Expression of peroxisome proliferator-activated receptor γ in renal cell carcinoma and growth inhibition by its agonists,” Biochemical and Biophysical Research Communications, vol. 287, no. 3, pp. 727–732, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Kawa, T. Nikaido, H. Unno, N. Usuda, K. Nakayama, and K. Kiyosawa, “Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR ligand troglitazone,” Pancreas, vol. 24, no. 1, pp. 1–7, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. M.-Y. Li, H. Deng, J.-M. Zhao, D. Dai, and X.-Y. Tan, “Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cell,” World Journal of Gastroenterology, vol. 9, no. 8, pp. 1683–1688, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Shimada, K. Kojima, K. Yoshiura, H. Hiraishi, and A. Terano, “Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells,” Gut, vol. 50, no. 5, pp. 658–664, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. T.-H. Chang and E. Szabo, “Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer,” Cancer Research, vol. 60, no. 4, pp. 1129–1138, 2000. View at Google Scholar · View at Scopus
  41. A. P. Heaney, M. Fernando, W. H. Yong, and S. Melmed, “Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas,” Nature Medicine, vol. 8, no. 11, pp. 1281–1287, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Tseng, “Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus,” Oncotarget, vol. 8, no. 2, pp. 3042–3048, 2017. View at Publisher · View at Google Scholar
  43. C.-H. Tseng, “Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes,” Annals of Medicine, vol. 45, no. 8, pp. 539–544, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. C.-H. Tseng, “Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese,” BMC Cancer, vol. 15, article 41, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. C.-H. Tseng, “Pioglitazone and bladder cancer: a population-based study of Taiwanese,” Diabetes Care, vol. 35, no. 2, pp. 278–280, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. C.-H. Tseng, “Pioglitazone does not affect the risk of ovarian cancer: analysis of a nationwide reimbursement database in Taiwan,” Gynecologic Oncology, vol. 131, no. 1, pp. 135–139, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. C.-H. Tseng, “Pioglitazone and oral cancer risk in patients with type 2 diabetes,” Oral Oncology, vol. 50, no. 2, pp. 98–103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. C.-H. Tseng, “Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes,” Metabolism: Clinical and Experimental, vol. 63, no. 8, pp. 1049–1055, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. C.-H. Tseng, “Pioglitazone and thyroid cancer risk in Taiwanese patients with type 2 diabetes,” Journal of Diabetes, vol. 6, no. 5, pp. 448–450, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Belfiore, M. Genua, and R. Malaguarnera, “PPAR-γ agonists and their effects on IGF-I receptor signaling: implications for cancer,” PPAR Research, vol. 2009, Article ID 830501, 18 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Zhao, H. B. Grossman, M. R. Spitz, S. P. Lerner, K. Zhang, and X. Wu, “Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk,” Journal of Urology, vol. 169, no. 2, pp. 714–717, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Tuccori, K. B. Filion, H. Yin, O. H. Yu, R. W. Platt, and L. Azoulay, “Pioglitazone use and risk of bladder cancer: Population Based Cohort Study,” BMJ, vol. 352, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. J. D. Lewis, L. A. Habel, C. P. Quesenberry et al., “Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes,” The Journal of the American Medical Association, vol. 314, no. 3, pp. 265–277, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. C.-H. Tseng, “Rosiglitazone is not associated with an increased risk of bladder cancer,” Cancer Epidemiology, vol. 37, no. 4, pp. 385–389, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Monami, I. Dicembrini, and E. Mannucci, “Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials,” Acta Diabetologica, vol. 51, no. 1, pp. 91–101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Bosetti, V. Rosato, D. Buniato, A. Zambon, C. La Vecchia, and G. Corrao, “Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis,” Oncologist, vol. 18, no. 2, pp. 148–156, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. D.-R. Yang, S.-J. Lin, X.-F. Ding et al., “Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion,” Urology, vol. 81, no. 5, pp. 1109.e1–1109.e6, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. L. McBeth, A. C. Nwaneri, M. Grabnar, J. Demeter, A. Nestor-Kalinoski, and T. D. Hinds, “Glucocorticoid receptor beta increases migration of human bladder cancer cells,” Oncotarget, vol. 7, no. 19, pp. 27313–27324, 2016. View at Publisher · View at Google Scholar · View at Scopus
  60. E. S. Costanzo, A. K. Sood, and S. K. Lutgendorf, “Biobehavioral influences on cancer progression,” Immunology and Allergy Clinics of North America, vol. 31, no. 1, pp. 109–132, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. R. R. Langley and I. J. Fidler, “Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis,” Endocrine Reviews, vol. 28, no. 3, pp. 297–321, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn, “Vascular endothelial growth factor and angiogenesis,” Pharmacological Reviews, vol. 56, no. 4, pp. 549–580, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. A. U. Hasan, K. Ohmori, K. Konishi et al., “Eicosapentaenoic acid upregulates VEGF-A through both GPR120 and PPARγ mediated pathways in 3T3-L1 adipocytes,” Molecular and Cellular Endocrinology, vol. 406, pp. 10–18, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Sankhwar, S. N. Sankhwar, A. Abhishek, and S. Rajender, “Clinical significance of the VEGF level in urinary bladder carcinoma,” Cancer Biomarkers, vol. 15, no. 4, pp. 349–355, 2015. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Roudnicky, C. Poyet, P. Wild et al., “Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis,” Cancer Research, vol. 73, no. 3, pp. 1097–1106, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Chang, P. Wu, R. Senthilkumar et al., “Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway,” Journal of Cancer Research and Clinical Oncology, vol. 142, no. 1, pp. 59–72, 2016. View at Publisher · View at Google Scholar · View at Scopus
  67. B. Jiang, E.-H. Li, Y.-Y. Lu et al., “Inhibition of fatty-acid synthase suppresses p-akt and induces apoptosis in bladder cancer,” Urology, vol. 80, no. 2, pp. 484.e9–484.e15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. R. M. Kaikaus, N. M. Bass, and R. K. Ockner, “Functions of fatty acid binding proteins,” Experientia, vol. 46, no. 6, pp. 617–630, 1990. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Furuhashi and G. S. Hotamisligil, “Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets,” Nature Reviews Drug Discovery, vol. 7, no. 6, pp. 489–503, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Lee, K. Wada, Y. Taniguchi et al., “Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma,” Oncology Reports, vol. 31, no. 3, pp. 1116–1120, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Adida and F. Spener, “Adipocyte-type fatty acid-binding protein as inter-compartmental shuttle for peroxisome proliferator activated receptor γ agonists in cultured cell,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1761, no. 2, pp. 172–181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. G. Ohlsson, J. M. A. Moreira, P. Gromov, G. Sauter, and J. E. Celis, “Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas,” Molecular and Cellular Proteomics, vol. 4, no. 4, pp. 570–581, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. J. E. Celis, M. Østergaard, B. Basse et al., “Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas,” Cancer Research, vol. 56, no. 20, pp. 4782–4790, 1996. View at Google Scholar · View at Scopus
  74. K. Cusi, “The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes,” Current Diabetes Reports, vol. 10, no. 4, pp. 306–315, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. C. M. Kusminski, S. Shetty, L. Orci, R. H. Unger, and P. E. Scherer, “Diabetes and apoptosis: lipotoxicity,” Apoptosis, vol. 14, no. 12, pp. 1484–1495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. V. L. Sundararaghavan, P. Sindhwani, and T. D. Hinds Jr., “Glucuronidation and UGT isozymes in bladder: new targets for the treatment of uroepithelial carcinomas?” Oncotarget, vol. 8, no. 2, pp. 3640–3648, 2016. View at Publisher · View at Google Scholar
  77. T. Suganami, M. Tanaka, and Y. Ogawa, “Adipose tissue inflammation and ectopic lipid accumulation,” Endocrine Journal, vol. 59, no. 10, pp. 849–857, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. V. R. Conde, P. F. Oliveira, A. R. Nunes et al., “The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism,” Experimental Cell Research, vol. 335, no. 1, pp. 91–98, 2015. View at Publisher · View at Google Scholar · View at Scopus
  79. Y. Shiomi, T. Yamauchi, M. Iwabu et al., “A novel peroxisome proliferator-activated receptor (PPAR)α agonist and PPARy antagonist, Z-551, ameliorates high-fat diet-induced obesity and metabolic disorders in mice,” Journal of Biological Chemistry, vol. 290, no. 23, pp. 14567–14581, 2015. View at Publisher · View at Google Scholar · View at Scopus
  80. T. D. Hinds, P. A. Hosick, M. W. Hankins, A. Nestor-Kalinoski, and D. E. Stec, “Mice with hyperbilirubinemia due to Gilbert's Syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα,” American Journal of Physiology—Endocrinology And Metabolism, 2016. View at Publisher · View at Google Scholar
  81. V. G. Maltarollo, M. Togashi, A. S. Nascimento, and K. M. Honorio, “Structure-based virtual screening and discovery of new PPARδ/γ dual agonist and PPARδ and γ agonists,” PLoS ONE, vol. 10, no. 3, Article ID e0118790, 2015. View at Publisher · View at Google Scholar · View at Scopus
  82. M. B. Oleksiewicz, J. Southgate, L. Iversen, and F. L. Egerod, “Rat urinary bladder carcinogenesis by dual-acting PPARα + γ agonists,” PPAR Research, vol. 2008, Article ID 103167, 14 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. F. L. Egerod, A. Bartels, N. Fristrup et al., “High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression,” BMC Cancer, vol. 9, article no. 385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. M. B. Oleksiewicz, I. Thorup, H. S. Nielsen et al., “Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo,” Toxicologic Pathology, vol. 33, no. 5, pp. 552–560, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Giampietro, A. D'Angelo, A. Giancristofaro et al., “Synthesis and structure-activity relationships of fibrate-based analogues inside PPARs,” Bioorganic and Medicinal Chemistry Letters, vol. 22, no. 24, pp. 7662–7666, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Hagiwara, S. Tamano, T. Ogiso, E. Asakawa, and S. Fukushima, “Promoting effect of the peroxisome proliferator, clofibrate, but not di(2-ethylhexyl)phthalate, on urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine,” Japanese Journal of Cancer Research, vol. 81, no. 12, pp. 1232–1238, 1990. View at Publisher · View at Google Scholar · View at Scopus
  87. C. E. Torrey, H. G. Wall, J. A. Campbell et al., “Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after oral administration—Part I,” International Journal of Toxicology, vol. 24, no. 5, pp. 313–325, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. N. Grankvist, R. E. Honkanen, Å. Sjöholm, and H. Ortsäter, “Genetic disruption of protein phosphatase 5 in mice prevents high-fat diet feeding-induced weight gain,” FEBS Letters, vol. 587, no. 23, pp. 3869–3874, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. T. D. Hinds Jr. and E. R. Sánchez, “Protein phosphatase 5,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 11, pp. 2358–2362, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. L. A. Stechschulte, C. Ge, T. D. Hinds, E. R. Sanchez, R. T. Franceschi, and B. Lecka-Czernik, “Protein phosphatase PP5 controls bone mass and the negative effects of rosiglitazone on bone through reciprocal regulation of PPARγ (peroxisome proliferator-activated receptor γ) and RUNX2 (runt-related transcription factor 2),” Journal of Biological Chemistry, vol. 291, no. 47, pp. 24475–24486, 2016. View at Publisher · View at Google Scholar
  91. H. Shirato, H. Shima, H. Nakagama et al., “Expression in hepatomas and chromosomal localization of rat protein phosphatase 5 gene,” International Journal of Oncology, vol. 17, no. 5, pp. 909–912, 2000. View at Google Scholar · View at Scopus
  92. T. Golden, I. V. Aragon, B. Rutland et al., “Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1782, no. 4, pp. 259–270, 2008. View at Publisher · View at Google Scholar · View at Scopus